Murat AFYON, CUMHUR ARTUK, Ercan YENİLMEZ, Berksan ŞİMŞEK, Ayper KAYA

The value of indirect serum markers in predicting severity of fibrosis in treatment naive patients with non-cirrhotic hepatitis C virus infection

We conducted this study for determining the value of indirect serum markers such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), INR (International Normalized Ratio) and platelet counts and the roles of the scores such as AST-to-ALT ratio (AAR), AST-to-platelet ratio index (APRI), FIB-4 index, King’s score, Goteborg University Cirrhosis Index (GUCI) and FibroQ in predicting severity of fibrosis in treatment naive patients with non-cirrhotic hepatitis C virus (HCV) infection. Treatment naive non-cirrhotic chronic HCV patients who underwent percutaneous liver biopsy between 01 January 2012 and 01 June 2015 were included in the study. For evaluating the difference in variables, patients were divided into 2 groups such as no or minimal fibrosis group (fibrosis score

PDF

___

1. Petta S, Craxi A. Current and future HCV therapy: do we still need other anti-HCV drugs? Liver Int. 2015;35(1):4–10.

2. Yenilmez E, Afyon M, Ulcay A, Ulus S, Kaya A, Erdem H. Evaluation of 135 liver biopsy results between 2011 and 2014, according to hepatitis B virus DNA and liver transaminase levels in naive young patients with HBeAg positive and negative chronic hepatitis B infection. Journal of Clinical Virology. 2015;69:235.

3. Kose S, Ersan G, Tatar B, Adar P, Sengel BE. Evaluation of Percutaneous Liver Biopsy Complications in Patients with Chronic Viral Hepatitis. Eurasian J Med. 2015;47(3):161-4.

4. Afyon M, Artuk C. Noninvasive indirect serum markers of liver fibrosis in patients with chronic viral hepatitis. Turk J Gastroenterol. 2016;27(4):397-8.

5. Stasi C, Milani S. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. World J Gastroenterol. 2016;22(4):1711-20.

6. Abdollahi M, Pouri A, Ghojazadeh M, Estakhri R, Somi M. Noninvasive serum fibrosis markers: A study in chronic hepatitis. Bioimpacts. 2015;5(1):17-23.

7. Vergara M, Bejarano G, Dalmau B, Gil M, Miquel M, SanchezDelgado J, Casas M, Puig J, Martinez-Bauer E, Dosal A, Lopez M, Moreno L, Valero O, Bella MR, Calvet X. Usefulness of indirect noninvasive methods in predicting progression to cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol. 2015;27(7):826-33.

8. Schmid P, Bregenzer A, Huber M, Rauch A, Jochum W, Müllhaupt B, Vernazza P, Opravil M, Weber R; Swiss HIV Cohort Study. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy. PLoS One. 2015;10(9):e0138838.

9. Karagoz E, Ulcay A, Tanoglu A, Kara M, Turhan V, Erdem H, Oncul O, Gorenek L. Clinical usefulness of mean platelet volume and red blood cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in chronic hepatitis B virus patients. Eur J Gastroenterol Hepatol. 2014;26(12):1320-4.

10. Eminler AT, Ayyildiz T, Irak K, Kiyici M, Gurel S, Dolar E, Gulten M, Nak SG. AST/ALT ratio is not useful in predicting the degree of fibrosis in chronic viral hepatitis patients. Eur J Gastroenterol Hepatol. 2015;27(12):1361-6.

11. Ceylan B, Mete B, Fincanci M, Aslan T, Akkoyunlu Y, Ozguneş N, Colak O, Gunduz A, Senates E, Ozaras R, Inci A, Tabak F. A new model using platelet indices to predict liver fibrosis in patients with chronic hepatitis B infection. Wien Klin Wochenschr. 2013;125(15- 16):453-60.

12. Tachi Y, Hirai T, Toyoda H, Tada T, Hayashi K, Honda T, Ishigami M, Goto H, Kumada T. Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus. PLoS One. 2015;10(7):e0133515.

13. Gökcan H, Kuzu UB, Öztaş E, Saygılı F, Öztuna D, Suna N, Tenlik İ, Akdoğan M, Kaçar S, Kılıç ZM, Kayaçetin E. The predictive value of noninvasive serum markers of liver fibrosis in patients with chronic hepatitis C. Turk J Gastroenterol. 2016;27(2):156-64.

14. Derbala M, Elbadri ME, Amer AM, AlKaabi S, Sultan KH, Kamel YM, Elsayed EH, Avades TY, Chandra P, Shebl FM. Aspartate transaminase to platelet ratio index in hepatitis C virus and Schistosomiasis coinfection. World J Gastroenterol. 2015;21(46):13132-9.

15. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-26.

16. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32-6.

17. Cross TJ, Rizzi P, Berry PA, Bruce M, Portmann B, Harrison PM. King's Score: an accurate marker of cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol. 2009;21(7):730-8.

18. D'Ambrosio R, Degasperi E, Aghemo A, Fraquelli M, Lampertico P, Rumi MG, Facchetti F, Grassi E, Casazza G, Rosenberg W, Bedossa P, Colombo M. Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. PLoS One. 2016;11(6):e0155967.

19. Erdogan S, Dogan HO, Sezer S, Uysal S, Ozhamam E, Kayacetin S, Koca Y. The diagnostic value of non-invasive tests for the evaluation of liver fibrosis in chronic hepatitis B patients. Scand J Clin Lab Invest. 2013;73(4):300-8.

20. Afyon M, Artuk C, Yenilmez E, Şimşek B, Kaya A. Evaluation of Platelet Incides in Young Male Patients with Hepatitis C. J Clin Anal Med. 2016;7(5):706-10.

21. Hsieh YY, Tung SY, Lee IL, Lee K, Shen CH, Wei KL, Chang TS, Chuang CS, Wu CS, Lin YH. FibroQ: an easy and useful noninvasive test for predicting liver fibrosis in patients with chronic viral hepatitis. Chang Gung Med J. 2009;32(6):614-22.

22. Kim WR, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, Janssen HL, Lampertico P, Lau D, Bornstein JD, Schall RE, Dinh P, Yee LJ, Martins EB, Lim SG, Loomba R, Petersen J, Buti M, Marcellin P. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64(4):773-80.

23. Yilmaz Y, Yonal O, Kurt R, Bayrak M, Aktas B, Ozdogan O. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease. Hepat Mon. 2011;11(2):103-6.

24. D'Souza RS, Neves Souza L, Isted A, Fitzpatrick E, Vimalesvaran S, Cotoi C, Amin S, Heaton N, Quaglia A, Dhawan A. AST-to-platelet ratio index in non-invasive assessment of long-term graft fibrosis following pediatric liver transplantation. Pediatr Transplant. 2016;20(2):222-6.

25. Orasan OH, Iancu M, Sava M, Saplontai-Pop A, Cozma A, Sarlea ST, Lungoci C, Ungureanu MI, Negrean V, Sampelean D, Dumitrascu DL. Non-invasive assessment of liver fibrosis in chronic viral hepatitis. Eur J Clin Invest. 2015;45(12):1243-51.

26. Kedia S, Bhatt VR, Rajan SK, Tandra PK, El Behery RA, Akhtari M. Benign and Malignant Hematological Manifestations of Chronic Hepatitis C Virus Infection. Int J Prev Med. 2014;5(3):179-92.